SAN FRANCISCO, July 25, 2017 -- Hagens Berman Sobol Shapiro LLP reminds investors in Axiom Holdings, Inc. (OTCQB:AIOM) of the August 21, 2017 Lead Plaintiff deadline in the pending securities class action.
If you purchased or otherwise acquired securities of AIOM between October 14, 2016 and June 19, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/AIOM
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On June 19, 2017, MarketWatch published a press release entitled “Axiom Holdings, Inc. Responds to SEC Subpoena and Updated Information.” According to the release, Curt Riley, Axiom’s CEO, reviewed numerous documents on CJC (Hong Kong), with whom the Company purports to have merged with, in response to an SEC subpoena. The release reported that the CEO of CJC signed the share exchange agreement between the companies after she resigned from CJC.
On June 20, 2017, TheStreet published a press release entitled “Axiom Board & CEO Is In The Process Of Rescinding Shares Related To CJC Reverse Merger, And Is Seeking A Court Injunction To Restrict Such Shares.” According to the release, Riley stated: “Regardless of many documents provided to our company, it now appears the merger was never completed, therefore, I, as CEO and the sole Director, am now taking steps to rescind the shares that were issued to the CJC shareholders including major shareholders Hu Deng Yang, Yang Chau, Jeffrey Martin, and Rex Cheung and will be investigating if such shares were used or sold without completing such transaction.”
These revelations drove the price of Axiom shares down almost 38% over two trading days to close at $0.72 on June 20, 2017.
“We’re watching facts as they unfold, particularly those related to the validity of the business combination with CJC,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Axiom should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Anta Sports Expands Global Footprint With Strategic Puma Stake
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Samsung Electronics Shares Jump on HBM4 Mass Production Report
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 



